References
- 1. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4):CD003566.10.1002/14651858.CD003566.pub2871935516235327
- 2. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.10.1136/bmj.d2549309148721558357
- 3. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880-887.10.1001/archinternmed.2010.11220498416
- 4. Hawkins NM, Petrie MC, Jhund MC, Chalmers GW, Dunn FG, McMurray JJV. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130-139.10.1093/eurjhf/hfn013263941519168510
- 5. Maclay D, MacNee W. Cardiovascular disease in COPD: Mechanisms. Chest. 2013;143:798-807.10.1378/chest.12-093823460157
- 6. Andell P, Koul S, Martinsson A, et al. Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction. Open Heart. 2014;1:e000002.10.1136/openhrt-2013-000002418934025332773
- 7. Díez JM, Morgan JC, García RJ. The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis. 2013;8:305-312.10.2147/COPD.S31236370078423847414
- 8. Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest. 2009;136:376-380.10.1378/chest.08-291819318666
- 9. Lipworth B, Skinner D, Devereux G, et al. Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease. Heart. doi:10.1136/heartjnl-2016-309458.10.1136/heartjnl-2016-309458513668627380949
- 10. Etminan M, Jafari S, Carleton B, Fitzgerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12:48.10.1186/1471-2466-12-48349944122947076
- 11. Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis. 2007;2:535-540.
- 12. Stone IS, Barnes NC, Petersen SE. Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease? Heart. 2012;98:1055-1106.
- 13. Chang CL, Mills GD, McLachlan JD, Karalus NC, Hancox RJ. Cardioselective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J. 2010;40:193-200.10.1111/j.1445-5994.2009.01943.x19383058
- 14. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between β-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischemic heart disease, heart failure or hypertension. Thorax. 2012;67:977-984.10.1136/thoraxjnl-2012-201945445461022941975
- 15. Su VY, Chang YS, Hu YW, Hung MH, et al. Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease. Medicine (Baltimore). 2016;95:e2427.10.1097/MD.0000000000002427474887126844454
- 16. Kubota Y, Asai K, Furuse E, et al. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:515-523.10.2147/COPD.S79942435670525784798
- 17. Quint JK, Herrett E, Bhaskaran K, et al. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ. 2013;347:f6650.10.1136/bmj.f6650389838824270505
- 18. Andell P, Erlinge D, Smith JG, et al. Beta-Blocker use and mortality in COPD patients after myocardial infarction: A Swedish Nationwide Observational Study. J Am Heart Assoc. 2015;4:e001611.10.1161/JAHA.114.001611457993725854796
- 19. Ni Y, Shi G, Wan H. Use of cardioselective beta-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res. 2012;40:2051-2065.10.1177/03000605120400060223321161
- 20. Farland MZ, Peters CJ, Williams JD, Bielak KM, Heidel RE, Ray SM. β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations. The Annals of Pharmacotherapy. 2013;47:651-656.10.1345/aph.1R60023585645
- 21. Campo G., Pavasini R, Biscaglia S, Contoli M, Ceconi C. Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease. Eur Heart J – Cardiovasc Pharmacother. 2015;1:205-211.10.1093/ehjcvp/pvv01927533997
- 22. Wellstein A, Palm D, Belz GG. Affinity and selectivity of beta-adrenoceptor antagonists in vitro. J Cardiovasc Pharmacol. 1986;8Suppl11:S36-S40.10.1097/00005344-198511001-000062439796